CAP Member Cornelia Ding, MD, FCAP discusses her recent work predicting prostate cancer grade reclassification. “The clinical management of localized prostate cancer is largely determined by pathology,” said Dr. Ding. “By interpreting prostate biopsies, we pathologists establish a diagnosis of prostate cancer as well as a grade group based on the evaluation of tumor architecture under the microscope using the Gleason grading system.”
For the full article click here: AI-based prostate cancer staging predicts active surveillance outcomes
